Skip to Content


Treatment for Pulmonary Hypertension

CoTherix, Inc. Announces Priority Review Designation by the FDA for Ventavis NDA

Ventavis Also Granted Orphan Drug Designation

Click here for more information on Ventavis

SOUTH SAN FRANCISCO, Calif., September 08, 2004 -- CoTherix, Inc. today announced that its New Drug Application (NDA) for Ventavis (iloprost) Inhalation Solution has been accepted for review by the U.S. Food and Drug Administration and has been granted priority review designation. The priority review designation establishes a target action date of December 31, 2004, for the Ventavis NDA. Additionally, CoTherix's request for orphan drug designation has been granted for the use of Ventavis to treat pulmonary arterial hypertension.

Ventavis is an inhaled formulation of iloprost, a prostacyclin analog. CoTherix is developing Ventavis for the treatment of pulmonary arterial hypertension, a highly debilitating disease characterized by severe constriction of the blood vessels of the lungs. Ventavis is currently marketed in various European countries and Australia by Schering AG, Germany. CoTherix licensed the exclusive U.S. rights to Ventavis from Schering AG in October 2003.

About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis is CoTherix's lead product candidate.

For further information, please visit

Posted: September 2004

Related Articles

Ventavis (iloprost) FDA Approval History